Biotech

All Articles

Amgen reports initial period 3 gain for $400M chronic eczema medication

.Amgen has shared (PDF) the initial stage 3 data on its own $400 thousand eczema drug, connecting th...

Biogen, UCB record period 3 lupus gain after neglecting earlier trial

.Biogen and also UCB's bet one's bottom dollar improving into period 3 on the back of a broken resea...

Aptadir wishes brand new RNA inhibitors can reverse complicated cancers cells

.Italian biotech Aptadir Therapeutics has launched along with the promise that its pipeline of precl...

Wave surfs DMD excellence to regulatory authorities' doors, delivering stock up

.Wave Life Sciences has actually satisfied its own goal in a Duchenne muscular dystrophy (DMD) resea...

Sanofi plucks new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma crease, us...

Achilles splashes cell therapy program, braces for unemployments after skipping 'commercial feasibility' goals

.Achilles Rehabs has torn up its own method. The English biotech is actually quiting working on its ...

Aligos declares stage 2 MASH win, lowering liver excess fat up to 46%

.Aligos Therapeutics is actually proclaiming a midstage win in metabolic-dysfunction affiliated stea...

Basilea scores $268M BARDA financing for antifungals, antibiotics

.Basilea Pharmaceutica's job cultivating brand new antifungals has received a considerable improveme...

Capricor sells Europe civil liberties to late-stage DMD therapy for $35M

.Possessing presently scooped up the USA liberties to Capricor Therapies' late-stage Duchenne muscle...

FDA fragments adcomm for Applied's uncommon illness drug

.After pushing the decision date for Applied Therapies' metabolic disorder drug govorestat, the FDA ...